Moderna Inc. (Nasdaq: MRNA)

https://www.modernatx.com

In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. *

	Start	2018-08-01 renamed
	Group	Moderna (Group)
	Predecessor	Moderna Therapeutics Inc.
	Industry	mRNA-based drug
	Industry 2	mRNA technology
	Person	Bancel, Stéphane (Moderna 2011– CEO before bioMérieux 201010 CEO + Eli Lilly)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	200 Technology Square
	City	02139 Cambridge, MA
	Tel	+1-617-714-6500
		Address record changed: 2024-01-05

Basic data	Employees	E: 501 to 1,000 (2020-02-12)
	Currency	USD
	Annual sales	60,209,000 (revenue, total, consolidated (2019) 2019-12-31)
	Profit	-514,021,000 (2019-12-31)
	Cash	1,103,000,000 (2019-12-31)

		* Document for »About Section«: Moderna, Inc.. (6/21/22). "Press Release: Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom". Cambridge, MA.

		Record changed: 2024-10-05